MindMed’s stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety

Business
0
Please log in or register to do it.


The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.



Your email address will not be published. Required fields are marked *

Short Seller Andrew Left Takes Aim At Square And The Crypto Market | CNBC
Coinbase shrugs off site crash as shares of the top U.S. crypto exchange surge